New Biological Therapeutics

2004 ◽  
pp. 149-457
Keyword(s):  
Biological Therapeutics

Molecular Design of Peptide-Fc Fusion Drugs

2019 ◽  
Vol 20 (3) ◽  
pp. 203-208 ◽  
Author(s):  
Lin Ning ◽  
Bifang He ◽  
Peng Zhou ◽  
Ratmir Derda ◽  
Jian Huang
Keyword(s):  
Rational Design ◽  
Molecular Design ◽  
Computational Design ◽  
Fusion Technology ◽  
Computational Tools ◽  
Open Questions ◽  
Biological Therapeutics ◽  
Key Steps ◽  
Computational Resources ◽  
Tools And Methods

Background:Peptide-Fc fusion drugs, also known as peptibodies, are a category of biological therapeutics in which the Fc region of an antibody is genetically fused to a peptide of interest. However, to develop such kind of drugs is laborious and expensive. Rational design is urgently needed.Methods:We summarized the key steps in peptide-Fc fusion technology and stressed the main computational resources, tools, and methods that had been used in the rational design of peptide-Fc fusion drugs. We also raised open questions about the computer-aided molecular design of peptide-Fc.Results:The design of peptibody consists of four steps. First, identify peptide leads from native ligands, biopanning, and computational design or prediction. Second, select the proper Fc region from different classes or subclasses of immunoglobulin. Third, fuse the peptide leads and Fc together properly. At last, evaluate the immunogenicity of the constructs. At each step, there are quite a few useful resources and computational tools.Conclusion:Reviewing the molecular design of peptibody will certainly help make the transition from peptide leads to drugs on the market quicker and cheaper.

scholarly journals The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications

2021 ◽  
Vol 22 (23) ◽  
pp. 12793
Author(s):  
Rohan Singh ◽  
Sindhuja Koppu ◽  
Patrick O. Perche ◽  
Steven R. Feldman
Keyword(s):  
Common Disease ◽  
Biological Therapies ◽  
Keratinocyte Proliferation ◽  
Psoriasis Plaque ◽  
Tnf Α ◽  
Systemic Inflammatory Disease ◽  
Biological Therapeutics ◽  
Prevalent Subtype ◽  
Molecular Pathophysiology

Psoriasis is the result of uncontrolled keratinocyte proliferation, and its pathogenesis involves the dysregulation of the immune system. The interplay among cytokines released by dendritic, Th1, Th2, and Th17 cells leads to the phenotypical manifestations seen in psoriasis. Biological therapies target the cytokine-mediated pathogenesis of psoriasis and have improved patient quality of life. This review will describe the underlying molecular pathophysiology and biologics used to treat psoriasis. A review of the literature was conducted using the PubMed and Google Scholar repositories to investigate the molecular pathogenesis, clinical presentation, and current therapeutics in psoriasis. Plaque psoriasis’, the most prevalent subtype of psoriasis, pathogenesis primarily involves cytokines TNF-α, IL-17, and IL-23. Pustular psoriasis’, an uncommon variant, pathogenesis involves a mutation in IL-36RN. Currently, biological therapeutics targeted at TNF-α, IL-12/IL-23, IL-17, and IL-23/IL-39 are approved for the treatment of moderate to severe psoriasis. More studies need to be performed to elucidate the precise molecular pathology and assess efficacy between biological therapies for psoriasis. Psoriasis is a heterogenous, chronic, systemic inflammatory disease that presents in the skin with multiple types. Recognizing and understanding the underlying molecular pathways and biological therapeutics to treat psoriasis is important in treating this common disease.

Biological Therapeutics

2013 ◽  
pp. 132-142
Author(s):  
Peter Lloyd ◽  
Jennifer Sims
Keyword(s):  
Biological Therapeutics

Biological therapeutics of AgO nanoparticles against pathogenic bacteria and A549 lung cancer cells

2019 ◽  
Vol 6 (10) ◽  
pp. 105402 ◽  
Author(s):  
L M Mahlaule-Glory ◽  
Z Mbita ◽  
M M Mathipa ◽  
Z N Tetana ◽  
N C Hintsho-Mbita
Keyword(s):  
Lung Cancer ◽  
Cancer Cells ◽  
Pathogenic Bacteria ◽  
Lung Cancer Cells ◽  
Biological Therapeutics ◽  
A549 Lung

scholarly journals Concise Review: Mending a Broken Heart: The Evolution of Biological Therapeutics

Stem Cells ◽  
2017 ◽  
Vol 35 (5) ◽  
pp. 1131-1140 ◽  
Author(s):  
Caressa Chen ◽  
Vittavat Termglinchan ◽  
Ioannis Karakikes
Keyword(s):  
Concise Review ◽  
Biological Therapeutics

Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies

2016 ◽  
Vol 98 ◽  
pp. 113-133 ◽  
Author(s):  
Bora Jang ◽  
Hyokyoung Kwon ◽  
Pramila Katila ◽  
Seung Jin Lee ◽  
Hyukjin Lee
Keyword(s):  
Cancer Therapies ◽  
Biological Therapeutics
Sign in / Sign up

Export Citation Format

Share Document